semaglutide oral cardiovascular indication news 2025 Long-Term SELECT Trial: Cuts Events by 20% beyond Weight Loss Frontiers | Effects of subcutaneous

Both interventions were assumed to be administered for a maximum of 2 years, with a non-responder stopping rule at 12 weeks (failure to achieve 5% weight loss from baseline) applied in line with STEP 8 ( Outcomes were expressed in terms of costs, life-years (LYs), quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratios (ICERs)

A higherdose formulation was later cleared in 2020 specifically for chronic weight management, marketed under the name Wegovy, but the active ingredient remains the same semaglutide molecule

GLP-1 agonists like semaglutide help to control your blood sugar, curb your appetite, and slow digestion

Est aprobado para diabetes tipo 2 y manejo crnico de peso en personas con obesidad o sobrepeso con comorbilidades relacionadas

Patience matters and so does restoring the right internal environment

Patients who discontinue GLP-1 medications should work with healthcare providers on sustainable weight maintenance strategies